{Reference Type}: Journal Article
{Title}: Safety of immune checkpoint inhibitors: An updated comprehensive disproportionality analysis and meta-analysis.
{Author}: Tyagi S;Kumar A;
{Journal}: Crit Rev Oncol Hematol
{Volume}: 200
{Issue}: 0
{Year}: 2024 May 27
{Factor}: 6.625
{DOI}: 10.1016/j.critrevonc.2024.104398
{Abstract}: <B>BACKGROUND: </B>The exact safety profile of Immune checkpoint inhibitors (ICIs) is unclear so far.<BR><B>OBJECTIVE: </B>The aim of the current study is to analyse the safety profile of ICIs in cancer patients.<BR><B>METHODS: </B>The updated comprehensive disproportionality analysis of post-marketing data using the FAERS database and meta-analysis of randomized clinical trials (RCTs) was conducted. Disproportionality measures were calculated in terms of PRR associated with chi-square value and ROR with 95% confidence intervals whereas overall estimate measures with 95% CIs, publication bias and heterogeneity were calculated using RevMan 5.4. The GRADE analysis was also done to check the quality of evidence for each outcome.<BR><B>RESULTS: </B>Various novel signals such as cholangitis, encephalitis, anuria, myelosuppression, and cachexia related to different system organ class were identified with ICIs. The sensitivity analysis results have indicated the influence of concomitant drugs on the identified signals. The meta-analysis results have shown a good safety profile of atezolizumab in non-small cell lung cancer (NSCLC) and melanoma, pembrolizumab in gastro-oesophageal cancer, urothelial cancer and head and neck squamous cell carcinoma (HNSCC), nivolumab in HNSCC as compared to the non-ICI group.<BR><B>CONCLUSIONS: </B>The safety of ICIs is dependent on their types as well as on the types of cancer.